Skip to main content

Colorectal Cancer: Bevacizumab

Volume 460: debated on Thursday 24 May 2007

To ask the Secretary of State for Health when she expects Bevacizumab to become routinely available on the NHS for the treatment of bowel cancer. (138598)

[holding answer 22 May 2007]: On 24 January 2007, the National Institute for Health and Clinical Excellence (NICE) issued guidance to the national health service on the use of Bevacizumab for the treatment of metastatic colorectal cancer.

NICE’s guidance did not recommend Bevacizumab as a treatment option for metastatic colorectal (bowel) cancer. However, the guidance states that patients who were receiving Bevacizumab should have the option to continue to do so until they and their consultants decide that it is the right time to stop treatment.

It will be for individual primary care trusts to decide whether to fund Bevacizumab for the treatment of metastatic colorectal cancer in the light of NICE’s recommendations. It would be inappropriate for Ministers to intervene.